tiprankstipranks
Advertisement
Advertisement
OnKure Maintained at Buy as Strategy Shifts to Next-Gen PI3Kα Inhibitors; $16 Price Target Reaffirmed
PremiumRatingsOnKure Maintained at Buy as Strategy Shifts to Next-Gen PI3Kα Inhibitors; $16 Price Target Reaffirmed
1M ago
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan
Premium
Company Announcements
OnKure Shareholders Approve Amended 2024 Equity Incentive Plan
3M ago
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
Premium
The Fly
OnKure Therapeutics downgraded to Hold from Buy at JonesResearch
4M ago
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
PremiumRatingsOnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
5M ago
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
Premium
The Fly
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
5M ago
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
Premium
The Fly
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
6M ago
OnKure Therapeutics files $200M mixed securities shelf
PremiumThe FlyOnKure Therapeutics files $200M mixed securities shelf
10M ago
OnKure Therapeutics Announces Sales Agreement with Leerink
Premium
Company Announcements
OnKure Therapeutics Announces Sales Agreement with Leerink
10M ago
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
Premium
The Fly
OnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100